Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.it.2011.03.008 http://scihub22266oqcxt.onion/10.1016/j.it.2011.03.008 C5414634!5414634!21530402     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21530402&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\21530402.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Trends+Immunol 2011 ; 32 (6): 272-7 Nephropedia Template TP {{tp|p=21530402|t=2011. Interferon-? exacerbates Th17 inflammatory diseases |pdf=|usr=}}{{21530402}} gab.com Text Interferon- exacerbates Th17 inflammatory diseases JO: Trends Immunol http://www.kidney.de/pget.php?&tw=1&pmid=21530402 #FOAvip Interferon-? (IFN-?) is the treatment most often prescribed for relapsing-remitting multiple sclerosis (RRMS). However, 30?50% of MS patients do not respond to IFN-?. In some cases, IFN-? exacerbates MS, and it consistently worsens neuromyelitis optica (NMO). In order to eliminate unnecessary treatment for patients non-responsive to IFN-?, and to avoid possible harm, researchers are identifying biomarkers that predict outcome prior to the initiation of treatment. These biomarkers reveal insights into mechanisms of disease. Recent discoveries on human samples from patients with RRMS, NMO, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and ulcerative colitis, indicate that IFN-? is ineffective and may worsen the clinical status in diverse diseases when a Th17 immune response is prominent. Twit Text FOAVip Interferon- exacerbates Th17 inflammatory diseases ????Trends Immunol http://www.kidney.de/pget.php?&tw=1&pmid=21530402 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=21530402 #FOAvip English Wikipedia <ref>{{Cite pmid|21530402}}</ref> Interferon-? exacerbates Th17 inflammatory diseases #MMPMID21530402 Axtell R; Raman C; Steinman L Trends Immunol 2011[Jun]; 32 (6): 272-7 PMID21530402show ga Interferon-? (IFN-?) is the treatment most often prescribed for relapsing-remitting multiple sclerosis (RRMS). However, 30?50% of MS patients do not respond to IFN-?. In some cases, IFN-? exacerbates MS, and it consistently worsens neuromyelitis optica (NMO). In order to eliminate unnecessary treatment for patients non-responsive to IFN-?, and to avoid possible harm, researchers are identifying biomarkers that predict outcome prior to the initiation of treatment. These biomarkers reveal insights into mechanisms of disease. Recent discoveries on human samples from patients with RRMS, NMO, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and ulcerative colitis, indicate that IFN-? is ineffective and may worsen the clinical status in diverse diseases when a Th17 immune response is prominent. äInterferon-? exacerbates Th17 inflammatory diseases (epmc).pdf DeepDyve Pubget Overpricing